PE52599A1 - Vacuna viva recombinante aviaria, que comprende como vector el virus de la laringotraqueitis infecciosa - Google Patents

Vacuna viva recombinante aviaria, que comprende como vector el virus de la laringotraqueitis infecciosa

Info

Publication number
PE52599A1
PE52599A1 PE1997000548A PE00054897A PE52599A1 PE 52599 A1 PE52599 A1 PE 52599A1 PE 1997000548 A PE1997000548 A PE 1997000548A PE 00054897 A PE00054897 A PE 00054897A PE 52599 A1 PE52599 A1 PE 52599A1
Authority
PE
Peru
Prior art keywords
promoter
virus
vector
proteins
cmvie
Prior art date
Application number
PE1997000548A
Other languages
English (en)
Inventor
Jean-Christophe Audonnet
Michel Bublot
Michel Riviere
Original Assignee
Rhone Merieux
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Merieux filed Critical Rhone Merieux
Publication of PE52599A1 publication Critical patent/PE52599A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/816—Viral vaccine for avian species, e.g. poultry or other birds

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

CARACTERIZADA PORQUE COMPRENDE Y EXPRESA UN PLASMIDO HETEROLOGO DEFINIDO ENTRE LOS NUCLEOTIDOS 1624 Y 3606 EN LA SEQ.ID NO:5, INSERTADA POR INSERCION SIMPLE O DESPUES DE SUPRESION TOTAL O PARCIAL DEL SITIO DE INSERCION EN EL QUE APARECE UN CUADRO ABIERTO (CAJA) DE LECTURA QUE COMPRENDE UN PROMOTOR , DOS O MAS GENES SEPARADOS DOS A DOS POR UN IRES (SITIO DE ENTRADA DEL RIBOSOMA INTERNO) Y UNA SENAL DE POLIADENILACION; PARA EXPRESAR EL PLASMIDO EL VECTOR COMPRENDE UN PROMOTOR EUCARIOTICO FUERTE CMV INMEDIATO TEMPRANO (IE) PREFERIBLEMENTE EL CMVIE MURINO O HUMANO. TAMBIEN SE REFIERE A DOS PLASMIDOS INSERTADOS EN EL SITIO DE INSERCION BAJO EL CONTROL DE PROMOTORES EUCARIOTICOS DIFERENTES, LA PRIMERA SECUENCIA ASOCIADA AL PROMOTOR CMVIE CON OTRO PROMOTOR DE MANERA QUE SUS EXTREMOS 5` SEAN ADYACENTES; QUE EXPRESAN UN POLIPEPTIDO ANTIGENICO, ELEGIDO DEL GRUPO QUE COMPRENDE PROTEINAS HN Y F DEL VIRUS DE LA ENFERMEDAD DE NEWCASTLE (NDV) Y LA GLICOPROTEINA gB, gD, GH+gL DEL VIRUS DE LA ENFERMEDAD DE MAREK (MDV), LA Vp2 DE LA ENFERMEDAD DE GUMBORO (IBDV) Y LAS PROTEINAS S Y M DEL VIRUS DE LA BRONQUITIS INFECCIOSA IBV
PE1997000548A 1996-06-27 1997-06-27 Vacuna viva recombinante aviaria, que comprende como vector el virus de la laringotraqueitis infecciosa PE52599A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9608243A FR2750866B1 (fr) 1996-06-27 1996-06-27 Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire

Publications (1)

Publication Number Publication Date
PE52599A1 true PE52599A1 (es) 1999-07-16

Family

ID=9493649

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1997000548A PE52599A1 (es) 1996-06-27 1997-06-27 Vacuna viva recombinante aviaria, que comprende como vector el virus de la laringotraqueitis infecciosa

Country Status (13)

Country Link
US (1) US6153199A (es)
EP (1) EP0914458A1 (es)
JP (1) JP2000512844A (es)
AR (1) AR008620A1 (es)
AU (1) AU739374B2 (es)
CO (1) CO4700303A1 (es)
FR (1) FR2750866B1 (es)
ID (1) ID18351A (es)
MA (1) MA24222A1 (es)
PE (1) PE52599A1 (es)
TN (1) TNSN97109A1 (es)
WO (1) WO1997049826A1 (es)
ZA (1) ZA975618B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6913751B2 (en) 1992-06-12 2005-07-05 Schering-Plough Veterinary Corporation Recombinant avian herpesvirus useful in vaccine production
US6632664B1 (en) 1997-10-03 2003-10-14 Nippon Zeon Co., Ltd. Avian infectious herpesvirus recombinants and recombinant vaccines prepared with the use of the same
AR031405A1 (es) * 2000-11-21 2003-09-24 Wyeth Corp Metodos y vacunas para conferir proteccion in ovo contra la rinotraqueitis del pavo
JP2002356441A (ja) * 2001-03-15 2002-12-13 Akzo Nobel Nv 組換え伝染性喉頭気管炎ウイルスワクチン
US7314715B2 (en) * 2001-06-14 2008-01-01 Schering-Plough Animal Health Corporation Recombinant avian herpesvirus useful in vaccine production
US20030157641A1 (en) * 2001-11-16 2003-08-21 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
CA2467363A1 (en) 2001-11-16 2003-06-12 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
EP1606419A1 (en) 2003-03-18 2005-12-21 Quantum Genetics Ireland Limited Systems and methods for improving protein and milk production of dairy herds
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
CA2545886A1 (en) 2003-11-13 2005-06-02 University Of Georgia Research Foundation, Inc. Methods of characterizing infectious bursal disease virus
US20050202484A1 (en) 2004-02-19 2005-09-15 The Governors Of The University Of Alberta Leptin promoter polymorphisms and uses thereof
ATE461710T1 (de) 2005-04-25 2010-04-15 Merial Ltd Nipah-virus-impfstoffe
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
EP3147296A1 (en) 2005-11-14 2017-03-29 Merial, Inc. Gene therapy for renal failure
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
CN102428099B (zh) 2009-04-03 2016-03-16 梅里亚有限公司 运载新城疫病毒的禽疫苗
EP2327764B1 (en) 2009-11-30 2011-12-28 United Cancer Research Institute New clone of Newcastle disease virus, its manufacture and its application in the medical treatment of cancer
EP3213766A1 (en) 2009-12-28 2017-09-06 Merial Ltd. Recombinant ndv antigen and uses thereof
US20130129780A1 (en) * 2010-08-02 2013-05-23 University Of Georgia Research Foundation, Inc. Modified infectious laryngotracheitis virus (iltv) and uses thereof
MX344103B (es) 2010-08-31 2016-12-05 Merial Ltd Vacunas de virus herpes vectorizado con virus de enfermedad de newcastle.
WO2012090073A2 (en) 2010-12-30 2012-07-05 The Netherlands Cancer Institute Methods and compositions for predicting chemotherapy sensitivity
EP2694678A2 (en) 2011-04-04 2014-02-12 Netherland Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
EP2694677A2 (en) 2011-04-04 2014-02-12 Netherland Cancer Institute Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
WO2012145577A1 (en) 2011-04-20 2012-10-26 Merial Limited Adjuvanted rabies vaccine with improved viscosity profile
KR102007444B1 (ko) 2011-04-25 2019-08-06 어드밴스드 바이오사이언스 라보라토리즈, 인코포레이티드 절단형 hiv 피막 단백질(env), 이와 관련된 방법 및 조성물
CA2837375C (en) 2011-06-01 2019-07-16 Merial Limited Needle-free administration of prrsv vaccines
ES2626297T3 (es) 2011-08-12 2017-07-24 Merial, Inc. Preservación asistida por vacío de productos biológicos, en particular de vacunas
WO2013093629A2 (en) 2011-12-20 2013-06-27 Netherlands Cancer Institute Modular vaccines, methods and compositions related thereto
WO2013138776A1 (en) 2012-03-16 2013-09-19 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
WO2014081958A1 (en) 2012-11-21 2014-05-30 Cardiomems, Inc. Devices, systems, and methods for pulmonary arterial hypertension (pah) assessment and treatment
EP2968514A1 (en) 2013-03-12 2016-01-20 Merial, Inc. Reverse genetics schmallenberg virus vaccine compositions, and methods of use thereof
US9198908B2 (en) 2013-03-15 2015-12-01 St. Jude Medical Luxembourg Holdings Ii S.A.R.L. (“Sjm Lux Ii”) Methods for the treatment of cardiovascular conditions
EP2845904A1 (en) * 2013-09-06 2015-03-11 Ceva Sante Animale Recombinant Marek's disease viruses and uses thereof
MX2017005687A (es) 2014-11-03 2017-08-21 Merial Inc Metodos para usar formulaciones para vacuna con microagujas para elicitar en animales inmunidad protectora contra virus de la rabia.
EP3313864B1 (en) 2015-06-23 2021-07-28 Boehringer Ingelheim Animal Health USA Inc. Prrsv minor protein-containing recombinant viral vectors and methods of making and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990002802A2 (en) * 1988-09-13 1990-03-22 Institute For Animal Health Limited Viral nucleotide sequences
WO1992003554A1 (en) * 1990-08-24 1992-03-05 Arthur Webster Pty. Ltd. Infectious laryngotracheitis virus vaccine
WO1993025655A1 (en) * 1992-06-12 1993-12-23 Genencor International, Inc. Enzymatic compositions and methods for producing stonewashed look on indigo-dyed denim fabric
WO1996000791A1 (en) * 1994-06-30 1996-01-11 The Board Of Trustees Of The University Of Illinois Recombinant infectious laryngotracheitis virus and vaccine
FR2728794B1 (fr) * 1994-12-30 1997-03-21 Rhone Merieux Vaccin recombinant aviaire a base de virus herpes aviaire, notamment contre la maladie de gumboro
CA2216139C (en) * 1995-03-23 2013-01-08 Syntro Corporation Recombinant infectious laryngotracheitis virus and uses thereof

Also Published As

Publication number Publication date
EP0914458A1 (fr) 1999-05-12
AU3448797A (en) 1998-01-14
AU739374B2 (en) 2001-10-11
FR2750866B1 (fr) 1998-11-27
MA24222A1 (fr) 1997-12-31
CO4700303A1 (es) 1998-12-29
FR2750866A1 (fr) 1998-01-16
TNSN97109A1 (fr) 2005-03-15
US6153199A (en) 2000-11-28
ZA975618B (en) 1998-12-28
AR008620A1 (es) 2000-02-09
WO1997049826A1 (fr) 1997-12-31
JP2000512844A (ja) 2000-10-03
ID18351A (id) 1998-04-02

Similar Documents

Publication Publication Date Title
PE52599A1 (es) Vacuna viva recombinante aviaria, que comprende como vector el virus de la laringotraqueitis infecciosa
Bayliss et al. A recombinant fowlpox virus that expresses the VP2 antigen of infectious bursal disease virus induces protection against mortality caused by the virus
CA2196570C (en) Recombinant herpesvirus of turkeys and uses thereof
US5182210A (en) Fowlpox virus promoters
US5223424A (en) Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence
EP0431668B1 (en) Recombinant herpesvirus of turkeys and live vector vaccines derived thereof
AU734085B2 (en) Recombinant live avian vaccine, using as vector the avian infectious laryngotracheitis virus.
Fodor et al. Induction of protective immunity in chickens immunised with plasmid DNA encoding infectious bursal disease virus antigens
AR013063A1 (es) Formula de vacuna aviaria, su utilizacion y kit de vacunacion
AU711813B2 (en) Avian herpesvirus-based live recombinant avian vaccine, in particular against Gumboro disease
AU670538B2 (en) Infectious bursal disease virus recombinant poxvirus vaccine
CA2283093A1 (en) Recombinant chimeric viruses and uses thereof
DE68912478D1 (de) Rekombinantes Marek-Krankheitsvirus, Verfahren zu seiner Herstellung, und Vakzine.
US5641490A (en) Infectious bursal disease virus recombinant poxvirus vaccine
US5374558A (en) Fowlpox virus promoter
Cavanagh Recent advances in avian virology
US5658572A (en) Infectious bursal disease virus recombinant poxvirus vaccine
US6136318A (en) Recombinant fowlpox viruses and uses thereof
KR100354972B1 (ko) 닭전염성기관지염 바이러스 ｓ1 단백질을 발현하는유전자재조합 마렉바이러스 및 그의 제조방법
AU750084B2 (en) Recombinant herpesvirus of turkeys and uses thereof II
RU99103126A (ru) Формула полинуклеотидной вакцины для птиц
ECSP972164A (es) Vacunas de uso aviario a base de virus de laringotraqueitis infecciosa
RU2019101007A (ru) Рекомбинантные непатогенные конструкции вируса болезни марека, кодирующие антигены вируса инфекционного ларинготрахеита и вируса инфекционного бурсита
AU7215900A (en) Recombinant fowlpox viruses and uses thereof
ECSP972183A (es) Formula de vacuna polinucleotidica aviaria

Legal Events

Date Code Title Description
FA Abandonment or withdrawal